127 related articles for article (PubMed ID: 36527933)
1. Discovery of tetrahydrofuranyl spirooxindole-based SMYD3 inhibitors against gastric cancer via inducing lethal autophagy.
Zhu HP; Chai J; Qin R; Leng HJ; Wen X; Peng C; He G; Han B
Eur J Med Chem; 2023 Jan; 246():115009. PubMed ID: 36527933
[TBL] [Abstract][Full Text] [Related]
2. Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy.
Shen B; Tan M; Mu X; Qin Y; Zhang F; Liu Y; Fan Y
Tumour Biol; 2016 Jun; 37(6):7371-81. PubMed ID: 26676636
[TBL] [Abstract][Full Text] [Related]
3. High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer.
Wang G; Huang Y; Yang F; Tian X; Wang K; Liu L; Fan Y; Li X; Li L; Shi B; Hao Y; Xia C; Nie Q; Xin Y; Shi Z; Ma L; Xu D; Liu C
Aging (Albany NY); 2020 Feb; 12(3):2030-2048. PubMed ID: 32007952
[TBL] [Abstract][Full Text] [Related]
4. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Mazur PK; Reynoird N; Khatri P; Jansen PW; Wilkinson AW; Liu S; Barbash O; Van Aller GS; Huddleston M; Dhanak D; Tummino PJ; Kruger RG; Garcia BA; Butte AJ; Vermeulen M; Sage J; Gozani O
Nature; 2014 Jun; 510(7504):283-7. PubMed ID: 24847881
[TBL] [Abstract][Full Text] [Related]
5. SMYD3-mediated lysine methylation in the PH domain is critical for activation of AKT1.
Yoshioka Y; Suzuki T; Matsuo Y; Nakakido M; Tsurita G; Simone C; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
Oncotarget; 2016 Nov; 7(46):75023-75037. PubMed ID: 27626683
[TBL] [Abstract][Full Text] [Related]
6. Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the Ras-ERK pathway.
Colón-Bolea P; Crespo P
Bioessays; 2014 Dec; 36(12):1162-9. PubMed ID: 25382779
[TBL] [Abstract][Full Text] [Related]
7. SMYD3 drives the proliferation in gastric cancer cells via reducing EMP1 expression in an H4K20me3-dependent manner.
Zeng Y; Ma G; Cai F; Wang P; Liang H; Zhang R; Deng J; Liu Y
Cell Death Dis; 2023 Jun; 14(6):386. PubMed ID: 37386026
[TBL] [Abstract][Full Text] [Related]
8. SMYD3: a regulator of epigenetic and signaling pathways in cancer.
Bernard BJ; Nigam N; Burkitt K; Saloura V
Clin Epigenetics; 2021 Feb; 13(1):45. PubMed ID: 33637115
[TBL] [Abstract][Full Text] [Related]
9. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B
Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925
[TBL] [Abstract][Full Text] [Related]
10. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening.
Gradl S; Steuber H; Weiske J; Szewczyk MM; Schmees N; Siegel S; Stoeckigt D; Christ CD; Li F; Organ S; Abbey M; Kennedy S; Chau I; Trush V; Barsyte-Lovejoy D; Brown PJ; Vedadi M; Arrowsmith C; Husemann M; Badock V; Bauser M; Haegebarth A; Hartung IV; Stresemann C
SLAS Discov; 2021 Sep; 26(8):947-960. PubMed ID: 34154424
[TBL] [Abstract][Full Text] [Related]
11. Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent inhibition of SMYD3.
Parenti MD; Naldi M; Manoni E; Fabini E; Cederfelt D; Talibov VO; Gressani V; Guven U; Grossi V; Fasano C; Sanese P; De Marco K; Shtil AA; Kurkin AV; Altieri A; Danielson UH; Caretti G; Simone C; Varchi G; Bartolini M; Del Rio A
Eur J Med Chem; 2022 Dec; 243():114683. PubMed ID: 36116234
[TBL] [Abstract][Full Text] [Related]
12. Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization.
Yoshioka Y; Suzuki T; Matsuo Y; Tsurita G; Watanabe T; Dohmae N; Nakamura Y; Hamamoto R
Cancer Med; 2017 Jul; 6(7):1665-1672. PubMed ID: 28639750
[TBL] [Abstract][Full Text] [Related]
13. Berberine represses human gastric cancer cell growth in vitro and in vivo by inducing cytostatic autophagy via inhibition of MAPK/mTOR/p70S6K and Akt signaling pathways.
Zhang Q; Wang X; Cao S; Sun Y; He X; Jiang B; Yu Y; Duan J; Qiu F; Kang N
Biomed Pharmacother; 2020 Aug; 128():110245. PubMed ID: 32454290
[TBL] [Abstract][Full Text] [Related]
14. Histone methyltransferase SMYD3 promotes MRTF-A-mediated transactivation of MYL9 and migration of MCF-7 breast cancer cells.
Luo XG; Zhang CL; Zhao WW; Liu ZP; Liu L; Mu A; Guo S; Wang N; Zhou H; Zhang TC
Cancer Lett; 2014 Mar; 344(1):129-137. PubMed ID: 24189459
[TBL] [Abstract][Full Text] [Related]
15. Discovery of an Allosteric Ligand Binding Site in SMYD3 Lysine Methyltransferase.
Talibov VO; Fabini E; FitzGerald EA; Tedesco D; Cederfeldt D; Talu MJ; Rachman MM; Mihalic F; Manoni E; Naldi M; Sanese P; Forte G; Lepore Signorile M; Barril X; Simone C; Bartolini M; Dobritzsch D; Del Rio A; Danielson UH
Chembiochem; 2021 May; 22(9):1597-1608. PubMed ID: 33400854
[TBL] [Abstract][Full Text] [Related]
16. Hit identification of SMYD3 enzyme inhibitors using structure-based pharmacophore modeling.
Alnabulsi SM; Al-Shar'i NA
Future Med Chem; 2019 May; 11(10):1107-1117. PubMed ID: 31280673
[No Abstract] [Full Text] [Related]
17. A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.
Peserico A; Germani A; Sanese P; Barbosa AJ; Di Virgilio V; Fittipaldi R; Fabini E; Bertucci C; Varchi G; Moyer MP; Caretti G; Del Rio A; Simone C
J Cell Physiol; 2015 Oct; 230(10):2447-2460. PubMed ID: 25728514
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design of a Novel SMYD3 Inhibitor that Bridges the SAM-and MEKK2-Binding Pockets.
Van Aller GS; Graves AP; Elkins PA; Bonnette WG; McDevitt PJ; Zappacosta F; Annan RS; Dean TW; Su DS; Carpenter CL; Mohammad HP; Kruger RG
Structure; 2016 May; 24(5):774-781. PubMed ID: 27066749
[TBL] [Abstract][Full Text] [Related]
19. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.
Rajajeyabalachandran G; Kumar S; Murugesan T; Ekambaram S; Padmavathy R; Jegatheesan SK; Mullangi R; Rajagopal S
Expert Opin Ther Targets; 2017 Feb; 21(2):145-157. PubMed ID: 28019723
[TBL] [Abstract][Full Text] [Related]
20. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.
Vieira FQ; Costa-Pinheiro P; Almeida-Rios D; Graça I; Monteiro-Reis S; Simões-Sousa S; Carneiro I; Sousa EJ; Godinho MI; Baltazar F; Henrique R; Jerónimo C
Oncotarget; 2015 May; 6(15):13644-57. PubMed ID: 25980436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]